Charles C. Searby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Charles C. Searby has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Val C. Sheffield
Division of Medical Genetics and Genomics, Department of Pediatrics, University of Iowa Hospitals & Clinics, Iowa City, Iowa
3 shared publications - Calvin S. Carter
Department of Neuroscience and Pharmacology, Carver College of Medicine, University of Iowa
2 shared publications - Danielle J. Foster
Stead Family Department of Pediatrics, University of Iowa Health Care
2 shared publications - Jennifer A. Petsche
Stead Family Department of Pediatrics, University of Iowa Health Care, Iowa City, IA 52242, USA; Interdisciplinary Graduate Program in Molecular Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
2 shared publications - Sunny C. Huang
Holden Comprehensive Cancer Center, Carver College of Medicine
2 shared publications - Terry G. Beltz
Department of Neuroscience and Pharmacology, Carver College of Medicine, University of Iowa
2 shared publications
Latest Publications
- 19 August 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 222,p. e68676
A Minimally Invasive Method for Generating a Syngeneic Orthotopic Mouse Model of Lung Cancer
Non-small cell lung cancer (NSCLC) continues to be the number one cause of cancer-related death for both women and men worldwide. More information needs to be gathered to understand the interactions between cancer cells, the immune system, the microenvironment within each tumor, and the host tissue to develop more effective treatment modalities. Reported here is a simple, repeatable method for inducing cancer within the mouse lung, allowing for the monitoring of tumor growth from early to late-stage disease. The surgical procedure involves a small superficial incision in the skin and an injection of cancer cells through the intercostal muscles into the lung. In vivo imaging systems (IVIS) in combination with cells engineered to express luciferase provide a convenient way of evaluating tumor growth and disease progression over the course of a study. This technique is easily transferable across various models of lung cancer and can be used to test the feasibility and efficacy of novel therapeutics in a preclinical model of lung cancer that mimics the natural tumor microenvironment. This broadens the relevance of both efficacy and safety/toxicity studies using standard-of-care treatments, including surgical resection, radiation, and immunotherapies in conjunction with experimental therapeutics.
- 19 August 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 222,p. e68676
A Minimally Invasive Method for Generating a Syngeneic Orthotopic Mouse Model of Lung Cancer
Non-small cell lung cancer (NSCLC) continues to be the number one cause of cancer-related death for both women and men worldwide. More information needs to be gathered to understand the interactions between cancer cells, the immune system, the microenvironment within each tumor, and the host tissue to develop more effective treatment modalities. Reported here is a simple, repeatable method for inducing cancer within the mouse lung, allowing for the monitoring of tumor growth from early to late-stage disease. The surgical procedure involves a small superficial incision in the skin and an injection of cancer cells through the intercostal muscles into the lung. In vivo imaging systems (IVIS) in combination with cells engineered to express luciferase provide a convenient way of evaluating tumor growth and disease progression over the course of a study. This technique is easily transferable across various models of lung cancer and can be used to test the feasibility and efficacy of novel therapeutics in a preclinical model of lung cancer that mimics the natural tumor microenvironment. This broadens the relevance of both efficacy and safety/toxicity studies using standard-of-care treatments, including surgical resection, radiation, and immunotherapies in conjunction with experimental therapeutics.
- 19 August 2025
- Published by MyJove Corporation
- No. 222,p. e68676
JoVE Video Dataset
Non-small cell lung cancer (NSCLC) continues to be the number one cause of cancer-related death for both women and men worldwide. More information needs to be gathered to understand the interactions between cancer cells, the immune system, the microenvironment within each tumor, and the host tissue to develop more effective treatment modalities. Reported here is a simple, repeatable method for inducing cancer within the mouse lung, allowing for the monitoring of tumor growth from early to late-stage disease. The surgical procedure involves a small superficial incision in the skin and an injection of cancer cells through the intercostal muscles into the lung. In vivo imaging systems (IVIS) in combination with cells engineered to express luciferase provide a convenient way of evaluating tumor growth and disease progression over the course of a study. This technique is easily transferable across various models of lung cancer and can be used to test the feasibility and efficacy of novel therapeutics in a preclinical model of lung cancer that mimics the natural tumor microenvironment. This broadens the relevance of both efficacy and safety/toxicity studies using standard-of-care treatments, including surgical resection, radiation, and immunotherapies in conjunction with experimental therapeutics.
- 19 August 2025
- Published by MyJove Corporation
- No. 222,p. e68676
JoVE Video Dataset
Non-small cell lung cancer (NSCLC) continues to be the number one cause of cancer-related death for both women and men worldwide. More information needs to be gathered to understand the interactions between cancer cells, the immune system, the microenvironment within each tumor, and the host tissue to develop more effective treatment modalities. Reported here is a simple, repeatable method for inducing cancer within the mouse lung, allowing for the monitoring of tumor growth from early to late-stage disease. The surgical procedure involves a small superficial incision in the skin and an injection of cancer cells through the intercostal muscles into the lung. In vivo imaging systems (IVIS) in combination with cells engineered to express luciferase provide a convenient way of evaluating tumor growth and disease progression over the course of a study. This technique is easily transferable across various models of lung cancer and can be used to test the feasibility and efficacy of novel therapeutics in a preclinical model of lung cancer that mimics the natural tumor microenvironment. This broadens the relevance of both efficacy and safety/toxicity studies using standard-of-care treatments, including surgical resection, radiation, and immunotherapies in conjunction with experimental therapeutics.
- Open Access
- 18 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (4) , 2398
Quantitative MRI Evaluation of Ferritin Overexpression in Non-Small-Cell Lung Cancer
Cancer cells frequently present elevated intracellular iron levels, which are thought to facilitate an enhanced proliferative capacity. Targeting iron metabolism within cancer cells presents an avenue to enhance therapeutic responses, necessitating the use of non-invasive models to modulate iron manipulation to predict responses. Moreover, the ubiquitous nature of iron necessitates the development of unique, non-invasive markers of metabolic disruptions to develop more personalized approaches and enhance the clinical utility of these approaches. Ferritin, an iron storage enzyme that is often upregulated as a response to iron accumulation, plays a central role in iron metabolism and has been frequently associated with unfavorable clinical outcomes in cancer. Herein, we demonstrate the successful utility, validation, and functionality of a doxycycline-inducible ferritin heavy chain (FtH) overexpression model in H1299T non-small-cell lung cancer (NSCLC) cells. Treatment with doxycycline increased the protein expression of FtH with a corresponding decrease in labile iron in vitro and in vivo, as determined by calcein-AM staining and EPR, respectively. Moreover, a subsequent increase in TfR expression was observed. Furthermore, T2* MR mapping effectively detected FtH expression in our in vivo model. These results demonstrate that T2* relaxation times can be used to monitor changes in FtH expression in tumors with bidirectional correlations depending on the model system. Overall, this study describes the development of an FtH overexpression NSCLC model and its correlation with T2* mapping for potential use in patients to interrogate iron metabolic alterations and predict clinical outcomes.
- 18 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (4) , 2398
Open AccessQuantitative MRI Evaluation of Ferritin Overexpression in Non-Small-Cell Lung Cancer
Cancer cells frequently present elevated intracellular iron levels, which are thought to facilitate an enhanced proliferative capacity. Targeting iron metabolism within cancer cells presents an avenue to enhance therapeutic responses, necessitating the use of non-invasive models to modulate iron manipulation to predict responses. Moreover, the ubiquitous nature of iron necessitates the development of unique, non-invasive markers of metabolic disruptions to develop more personalized approaches and enhance the clinical utility of these approaches. Ferritin, an iron storage enzyme that is often upregulated as a response to iron accumulation, plays a central role in iron metabolism and has been frequently associated with unfavorable clinical outcomes in cancer. Herein, we demonstrate the successful utility, validation, and functionality of a doxycycline-inducible ferritin heavy chain (FtH) overexpression model in H1299T non-small-cell lung cancer (NSCLC) cells. Treatment with doxycycline increased the protein expression of FtH with a corresponding decrease in labile iron in vitro and in vivo, as determined by calcein-AM staining and EPR, respectively. Moreover, a subsequent increase in TfR expression was observed. Furthermore, T2* MR mapping effectively detected FtH expression in our in vivo model. These results demonstrate that T2* relaxation times can be used to monitor changes in FtH expression in tumors with bidirectional correlations depending on the model system. Overall, this study describes the development of an FtH overexpression NSCLC model and its correlation with T2* mapping for potential use in patients to interrogate iron metabolic alterations and predict clinical outcomes.
- Open Access
- 8 March 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (5)
Autophagy stimulation reduces ocular hypertension in a murine glaucoma model via autophagic degradation of mutant myocilin
Elevation of intraocular pressure (IOP) due to trabecular meshwork (TM) damage is associated with primary open-angle glaucoma (POAG). Myocilin mutations resulting in elevated IOP are the most common genetic causes of POAG. We have previously shown that mutant myocilin accumulates in the ER and induces chronic ER stress, leading to TM damage and IOP elevation. However, it is not understood how chronic ER stress leads to TM dysfunction and loss. Here, we report that mutant myocilin activated autophagy but was functionally impaired in cultured human TM cells and in a mouse model of myocilin-associated POAG ( Tg-MYOC Y437H ). Genetic and pharmacological inhibition of autophagy worsened mutant myocilin accumulation and exacerbated IOP elevation in Tg-MYOC Y437H mice. Remarkably, impaired autophagy was associated with chronic ER stress–induced transcriptional factor CHOP. Deletion of CHOP corrected impaired autophagy, enhanced recognition and degradation of mutant myocilin by autophagy, and reduced glaucoma in Tg-MYOC Y437H mice. Stimulating autophagic flux via tat-beclin 1 peptide or torin 2 promoted autophagic degradation of mutant myocilin and reduced elevated IOP in Tg-MYOC Y437H mice. Our study provides an alternate treatment strategy for myocilin-associated POAG by correcting impaired autophagy in the TM.
- 8 March 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (5)
Open AccessAutophagy stimulation reduces ocular hypertension in a murine glaucoma model via autophagic degradation of mutant myocilin
Elevation of intraocular pressure (IOP) due to trabecular meshwork (TM) damage is associated with primary open-angle glaucoma (POAG). Myocilin mutations resulting in elevated IOP are the most common genetic causes of POAG. We have previously shown that mutant myocilin accumulates in the ER and induces chronic ER stress, leading to TM damage and IOP elevation. However, it is not understood how chronic ER stress leads to TM dysfunction and loss. Here, we report that mutant myocilin activated autophagy but was functionally impaired in cultured human TM cells and in a mouse model of myocilin-associated POAG ( Tg-MYOC Y437H ). Genetic and pharmacological inhibition of autophagy worsened mutant myocilin accumulation and exacerbated IOP elevation in Tg-MYOC Y437H mice. Remarkably, impaired autophagy was associated with chronic ER stress–induced transcriptional factor CHOP. Deletion of CHOP corrected impaired autophagy, enhanced recognition and degradation of mutant myocilin by autophagy, and reduced glaucoma in Tg-MYOC Y437H mice. Stimulating autophagic flux via tat-beclin 1 peptide or torin 2 promoted autophagic degradation of mutant myocilin and reduced elevated IOP in Tg-MYOC Y437H mice. Our study provides an alternate treatment strategy for myocilin-associated POAG by correcting impaired autophagy in the TM.